Evidence-Based Summary
Pramlintide is an approved, short-acting amylin analogue used before meals alongside insulin; in year-long trials it modestly lowered HbA1c and body weight in people with type 1 or type 2 diabetes. Cagrilintide is a long-acting, investigational amylin analogue built to last a week. In a 26-week phase 2 obesity trial, cagrilintide groups lost 6.0% to 10.8% of body weight versus 3.0% with placebo; in pramlintide's obesity studies, placebo-corrected weight loss was 3.7% at 16 weeks and 5.6% to 6.8% at 12 months among people who completed treatment. Those are different trials, populations and analyses, so they are not directly comparable, and pramlintide is not approved for weight loss. In cell studies cagrilintide also activates the calcitonin receptor, whereas pramlintide is selective for amylin receptors. No trial has compared them directly.
Quick Comparison: Cagrilintide vs Pramlintide
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Cagrilintide | Pramlintide |
|---|---|---|
| Class | Investigational long-acting (lipidated) amylin analogue | Approved short-acting amylin analogue |
| Target receptors | Amylin receptors and the calcitonin receptor (nonselective, in cell studies) | Amylin receptors (selective, in the same cell studies) |
| How it is given | Once-weekly injection under the skin, in trials only | Injection under the skin before major meals, several times a day |
| U.S. regulatory status (October 2026) | Not FDA-approved, alone or as CagriSema | FDA-approved (Symlin) as an add-on for type 1 or type 2 diabetes in people using mealtime insulin |
| Strongest human evidence | Phase 2 obesity trial alone; phase 3 trials mainly as part of CagriSema | Year-long randomized trials in type 1 and type 2 diabetes |
| Main safety concerns | Gastrointestinal effects, mainly nausea; administration-site reactions | Boxed warning: severe hypoglycemia when used with insulin; nausea |
| Approved for weight loss? | No | No; weight loss was studied but is not a labelled use |
| WADA status (2026 List) | Not named; as a drug with no regulatory approval it may fall under S0 (non-approved substances) | Not named on the 2026 Prohibited List |
Same Hormone Family, Different Design
Amylin slows stomach emptying, limits the rise in glucagon after meals and promotes fullness. Natural amylin clumps into fibrils, so both drugs are modified versions designed to stay stable.
Cagrilintide
Primary Target: Amylin receptors and the calcitonin receptor
Affinity Profile: Nonselective amylin/calcitonin receptor agonist (cell studies)
A fatty-acid chain (lipidation) extends its action so it can be given weekly. In a cell-based comparison, it showed a distinct profile from pramlintide, activating calcitonin receptors as well as amylin receptors. These are laboratory findings.
Pramlintide
Primary Targets: Amylin receptors
Affinity Profile: Amylin-receptor selective (cell studies)
Short half-life, so it is injected before meals. It reduces the after-meal glucagon rise and slows stomach emptying, which lowers post-meal glucose in people using insulin.
FDA Status: Symlin Approved, Cagrilintide Not
United States status checked 11 October 2026.
Cagrilintide Status & Formulations
Not FDA-approved, alone or combined with semaglutide (CagriSema); no record appears in Drugs@FDA or DailyMed. FDA states cagrilintide is not a component of any FDA-approved drug and cannot be used in compounding.
Pramlintide Status & Formulations
Symlin (pramlintide acetate) injection is indicated as an adjunctive treatment for people with type 1 or type 2 diabetes who use mealtime insulin and have not achieved desired glucose control despite optimal insulin therapy. The label carries a boxed warning for severe hypoglycemia.
Critical Regulatory Distinction
Pramlintide's approval covers diabetes management with mealtime insulin, not weight loss. Cagrilintide has no approved use.
Diabetes Trials vs Obesity Trials
Pramlintide was tested mainly as an add-on to insulin in diabetes; cagrilintide mainly for weight in people without diabetes. Figures from different trials are not directly comparable.
Cagrilintide: Clinical Evidence Overview
In a 26-week phase 2 trial in adults with overweight or obesity without diabetes (706 on cagrilintide), weight fell 6.0% to 10.8% across five dose levels vs 3.0% with placebo, and the top dose group lost more than liraglutide (10.8% vs 9.0%). In a 32-week phase 2 trial in type 2 diabetes, cagrilintide alone lowered HbA1c 0.9 percentage points and weight 8.1%. Most phase 3 data (REDEFINE, REIMAGINE) test it combined with semaglutide. Funded by Novo Nordisk.
Pramlintide: Clinical Evidence Overview
In type 1 diabetes (480 patients, 52 weeks), pramlintide added to insulin lowered HbA1c 0.67 points at week 13 vs 0.16 with placebo, with a sustained placebo-corrected difference at week 52 and average weight loss rather than gain. In insulin-treated type 2 diabetes (656 patients, 52 weeks), the best-performing regimen lowered HbA1c 0.62 points with weight change of −1.4 kg vs +0.7 kg on placebo. In obesity studies (not an approved use), placebo-corrected weight loss was 3.7% at 16 weeks and 5.6% to 6.8% at 12 months among completers.
Curated Clinical Evidence Table
A curated selection of the primary studies behind each compound’s evidence profile. Results from different studies are not directly comparable.
| Study & Citation | Population | Comparison & Dosing | Duration | Main Endpoint | Key Finding | Methodological Limitations |
|---|---|---|---|---|---|---|
| Cagrilintide phase 2 (Lau et al., Lancet 2021) | Adults with overweight or obesity, without diabetes; 706 on cagrilintide | Cagrilintide (five dose levels) vs liraglutide vs placebo | 26 weeks | Percent change in body weight | −6.0% to −10.8% vs −3.0% with placebo; top dose 10.8% vs liraglutide 9.0%. | Short; industry funded; not compared with pramlintide. |
| Phase 2 three-arm trial (Frias et al., Lancet 2023) | 92 adults with type 2 diabetes on metformin | Cagrilintide alone vs semaglutide alone vs combination | 32 weeks | HbA1c change; weight change | Cagrilintide alone: HbA1c −0.9 points, weight −8.1%. | Small; not an insulin-treated population. |
| Pramlintide in type 1 diabetes (Whitehouse et al., Diabetes Care 2002) | 480 patients with type 1 diabetes on insulin | Pramlintide vs placebo before meals, added to insulin | 52 weeks plus open-label extension | HbA1c change | −0.67 vs −0.16 points at week 13; placebo-corrected difference sustained at week 52; average weight loss. | Older trial; severe hypoglycemia remains a labelled risk with insulin. |
| Pramlintide in type 2 diabetes (Hollander et al., Diabetes Care 2003) | 656 insulin-treated patients with type 2 diabetes | Pramlintide regimens vs placebo, added to insulin | 52 weeks | HbA1c change | Best regimen: −0.62 points at week 52; weight −1.4 kg vs +0.7 kg with placebo. | Modest effect; insulin-treated population only. |
| Pramlintide in obesity (Aronne et al., J Clin Endocrinol Metab 2007) | 204 adults with obesity | Pramlintide vs placebo, no lifestyle program | 16 weeks | Weight change | Placebo-corrected weight loss 3.7% among completers; 31% lost at least 5% vs 2%. | Short; completers analysis; weight loss is not an approved use. |
| Pramlintide in obesity, 12 months (Smith et al., Diabetes Care 2008) | 411 adults with obesity, with lifestyle intervention | Several pramlintide regimens vs placebo | 4 months plus 8-month single-blind extension | Weight change | Placebo-corrected loss of 5.6% to 6.8% at 12 months in two regimens (146 evaluable). | Many participants not in the 12-month evaluable group; not an approved use. |
Hypoglycemia Risk vs Gastrointestinal Effects
Pramlintide's main risk comes from its use with insulin. Cagrilintide has mostly been studied in people not using insulin, so the two safety profiles were measured in very different settings.
Pramlintide only: Boxed Warning for severe hypoglycemia
Symlin used with insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes, usually within 3 hours of an injection. Patient selection, careful instruction and insulin adjustment are part of the label. Cagrilintide has no FDA label, so no labelled warnings exist for it; that is not evidence that it is safer.
| Safety Consideration | Cagrilintide | Pramlintide |
|---|---|---|
| Most common adverse effects | Nausea, constipation, diarrhoea and administration-site reactions; gastrointestinal events 41%–63% vs 32% with placebo | Nausea, usually mild and early; 9%–29% vs 2% with placebo in a 4-month obesity study |
| Hypoglycemia | Not a prominent signal in obesity trials without insulin; no level 2 or 3 hypoglycemia in the 32-week diabetes trial | Boxed warning when used with insulin |
| Treatment burden | Weekly injection (trials) | Injection before each major meal |
| Long-term safety data | Limited; no approved label | Marketed product with label and post-marketing experience |
What Cagrilintide and Pramlintide Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Amylin analogues
Both mimic amylin to slow stomach emptying, reduce after-meal glucagon and promote fullness.
Nausea
Nausea is the most common side effect of both.
Engineered for stability
Both were modified to avoid the fibril formation of natural amylin.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Duration of action
Pramlintide is short-acting and needs mealtime injections; cagrilintide was lipidated for weekly use.
Receptor selectivity
In cell studies, cagrilintide activates calcitonin as well as amylin receptors; pramlintide is amylin-receptor selective.
Approved use
Pramlintide is approved for diabetes with mealtime insulin; cagrilintide is investigational, mainly for weight.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
Pramlintide is an approved weight-loss drug
Not supportedSymlin label: adjunct for type 1 or type 2 diabetes in people using mealtime insulin.
Pramlintide reduced weight in obesity trials, but its FDA approval covers diabetes management with mealtime insulin only.
Cagrilintide is just a once-weekly pramlintide
OversimplifiedCagrilintide is not FDA-approved.
Both are amylin analogues, but cagrilintide was redesigned with lipidation and, in cell studies, has a different receptor profile. Its clinical effects come from its own trials.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Glucose control in diabetes
Pramlintide is approved on year-long trials with insulin; cagrilintide alone has one small phase 2 diabetes trial.
Weight reduction
Cagrilintide alone has phase 2 data (phase 3 mainly with semaglutide); pramlintide's obesity trials were short or completer-based and did not lead to approval.
Cagrilintide vs pramlintide directly
No head-to-head clinical trial; only a cell-based pharmacology comparison.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
No direct trial
No study has compared the two drugs in people.
Cagrilintide with insulin
Whether cagrilintide carries hypoglycemia risk similar to pramlintide when combined with insulin has not been established in published trials.
Role of calcitonin-receptor activity
The difference in receptor profile comes from cell studies; whether it explains differences in human weight loss is unknown.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Phase 2 randomized controlled trial
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
-
Phase 2 randomized controlled trial · Three-arm
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialArticle title reproduced as published; it is not dosing guidance.
-
In vitro receptor pharmacology
AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective AgonistsAM833 is cagrilintide; compared with pramlintide in cell assays. Funded by Novo Nordisk.
-
Medicinal chemistry
Development of Cagrilintide, a Long-Acting Amylin Analogue
-
Randomized controlled trial
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
-
Randomized controlled trial
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial
-
Phase 2 randomized controlled trial
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study
-
Randomized controlled trial
Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity
-
Official U.S. prescribing information
SymlinPen (pramlintide acetate) injection, current U.S. labelLabel published 20 August 2024; checked 11 October 2026.
-
FDA safety communication
FDA's concerns with unapproved GLP-1 drugs used for weight lossIncludes FDA's statement on cagrilintide.